NHS Female Sterilisation Policy: The FOI Disclosure Says the February 2026 Policy Was Based on 2024 Work — So Where Is the Evidence of Reform?

A note about my conclusions: this article distinguishes carefully between “there is no evidence this happened” and “the ICB did not disclose evidence that it happened.” Where records have not been supplied, I do not automatically claim they never existed. I am asking a more basic accountability question: if senior NHS leadership says these actions were completed and the records exist, why were those records not produced in an FOI specifically asking for evidence of compliance?

What did I actually ask NHS Thames Valley ICB for?

My Freedom of Information request was deliberately titled:

I was not asking for another assurance that the NHS had learned lessons. They pulled the wool over people's eyes in the media attention that exploded after the Ombudsman's report.

But I wanted the paper trail.

I asked for the final decision and approval material, equality assessment, clinical and legal rationale, evidence relating to the NHS Constitution and relevant guidance, consideration of bodily autonomy and informed choice, comparison with vasectomy, and — crucially — evidence that the revised policy-development processes introduced after the Ombudsman investigation had actually been applied.

I also deliberately asked that, if those improved processes had not been completed before the February 2026 policy was approved, the ICB provide the recorded justification, timetable and plans for completing them.

That last part matters enormously now.

What does the ICB's own FOI response admit about the February 2026 policy?

This is, in my view, the most important part of the entire disclosure.

The evidence they disclosed clearly states:

the February 2026 policy “was based on a recommendation from SERPC in December 2024” and “does not reflect process changes adopted since February 2026.”

The response also says that SERPC-04 v1.0 was recommended in December 2024 and therefore would not reflect the findings or recommendations of the PHSO report - with provisional views which they received in August 2025, and the final report published in December 2025.

That changes the question completely.

The February 2026 policy was introduced after the Ombudsman investigation had already exposed serious problems in the previous decision-making process.

But the ICB's own response now confirms that the policy adopted in February was still based on the December 2024 SERPC work.

The January 2026 Quality Oversight Group paper says the commissioning position had undergone its “full evidence review” at SERPC in December 2024. The supporting documents listed for adoption were likewise the December 2024 report, the old SERPC Equality Impact Assessment and the related supporting information.

What post-Ombudsman evidence is not in the disclosure?

I do not see disclosed:

• a new post-PHSO evidence review;
• a new post-PHSO equality assessment;
• a post-PHSO comparison of the male and female sterilisation pathways;
• a post-PHSO legal analysis;
• a post-PHSO NHS Constitution analysis;
• a post-PHSO autonomy/informed-consent analysis;
• a new consultation exercise;
• the documented SERPC feedback on the PHSO findings;
• the 10 February 2026 SERPC record showing how those findings were considered before ratification;
• the 11 February 2026 SERGG record;
• a revised decision rationale showing why the therapeutic LARC trial remained justified after the Ombudsman's findings;
• or the actual completed decision/ratification record showing what QOG members decided and on what evidence.

And their response actually admits one especially important absence: the requested female-versus-vasectomy comparison was not conducted in the 2024 supporting material.

That is significant because one of the Ombudsman's findings concerned the failure to consider female sterilisation fairly and consistently alongside male sterilisation.

So what did CEO Nick Broughton say had been done?

This is where the story becomes much more difficult for the ICB.

The claims made by CEO Dr Nick Broughton in his letters to me and to the Ombudsman after the PHSO investigation about work said to have been completed were not supported by the documents supplied in my explicit FOI request seeking to establish evidence of compliance with the revised policy-development processes.

Some things are corroborated. Some were explicitly still “in progress”. But for a striking number of actions described as completed, documented or formally agreed, the documents that should evidence those claims were not supplied in my FOI disclosure.

And you'd understand my cynicism now - but while we laugh off the ''Picture or it didn't happen''  when people make selfies in important life moments - I ask for EVIDENCE - or it didn't happen! Because we have an established and shockingly long record of CEO Nick Broughton making claims he cannot support with Evidence. 

So - here's the breakdown of what he has claimed in his letters to myself and the Ombudsman, and what we've actually got documentary evidence for in the disclosure.

 

Date: Nick Broughton's Letters	What he said had happened or was happening	Documentary evidence actually supplied in FOI-TV-2606-105?	My assessment
13 January 2026	PHSO report had been sent to the Third Committee chair/admins on 2 January, who were preparing it for dissemination to the committee.	No underlying email, circulation record, acknowledgement or dissemination record supplied.	❌ Claim only in Broughton’s letter.
13 January 2026	The ICB would “comply fully” with the PHSO recommendations.	The later disclosure expressly says SERPC-04 v1.0 was based on the December 2024 recommendation and therefore would not reflect the PHSO findings/recommendations.	⚠️ The disclosure materially undermines any suggestion that the February policy itself represented full substantive implementation.
16 February 2026	Revised SERPC-04 had been ratified by BOB ICB.	A 6 January QOG cover paper requesting a virtual decision was disclosed, but I have not seen the resulting decision/email vote/ratification record itself.	🟡 Ratification is asserted and later repeated, but the actual decision record was not supplied.
16 February 2026	Providers would be notified; a GP Bulletin issued; prior-approval form uploaded, with March implementation dates.	No provider notification, GP Bulletin, Blueteq upload record or implementation confirmation supplied.	❌ No documentary proof in the disclosure.
16 February 2026	BOB asked SERPC/SERGG to circulate PHSO findings and obtain feedback on whether SERPC’s process required improvement.	No request/circulation email or feedback request supplied.	❌
16 February 2026	“All feedback received was documented” and discussed at SERPC on 10 February and SERGG on 11 February.	No feedback, 10 February SERPC minutes, 11 February SERGG minutes, agenda papers or action records supplied.	❌ This is one of the strongest missing-record issues because he expressly says the material was documented.
16 February 2026	SERPC agreed a further review of SERPC-04, including patient choice.	The FOI response later confirms that a further review happened and a refreshed report existed.	🟡 Event corroborated, underlying evidence withheld.
16 February 2026	Terms of Reference to Planning Group 24 February; policy review 14 April; draft sign-off 22 April; issue to ICBs 30 April; implementation estimated by end May.	No 24 February ToR/planning record, April agenda/minutes, 22 April circulation or 30 April issue record supplied. The FOI response confirms a refreshed April report existed but excludes it.	⚠️ They supplied the timetable in a letter, but not the records showing the work.
16 April 2026 – overarching claim	Remedial work had been “systematically recorded within an action tracker comprising 14 discrete items.”	The 14-item action tracker itself was not supplied.	❌ Major omission. This is the central record that should evidence the claimed remediation.
Action 1 – Equity considerations	Complete: updated Terms of Reference contained explicit prompt to consider equivalent procedures for both genders; ToR reviewed in March.	No updated ToR, March review record or related template supplied.	❌
Action 2 – Action logging	Complete: actions listed on April SERPC and Policy Development Governance Group agendas; details captured in trackers.	Neither April agenda, Governance Group agenda nor action tracker supplied.	❌ They identify the exact records that supposedly prove it; none were disclosed.
Action 3 – Prioritising reviews	Complete: March SERPC work programme updated to prioritise reviews where equality issues were identified.	No March SERPC work programme or minutes supplied.	❌
Action 4 – Recording decision rationale	Complete: documentation updated and in use from April; decisions to record evidence/guidance departures and equality impact.	No updated template/documentation supplied. No April deliberation record supplied. The FOI response says the refreshed April report existed, but withholds it.	⚠️ Potential evidence exists by their own admission, but it was not disclosed.
Action 5 – Ethical Framework	Complete: Ethical Framework circulated with April agenda; slides added to committee template; ongoing.	No April agenda, circulated framework, updated template or slides supplied. The only ethical material disclosed relates to the older 2024 process.	❌
Action 6 – Comparison between treatments	Complete: report templates now prompt comparative prices and offset costs.	No revised report template supplied. The FOI response also confirms that the female-vs-vasectomy comparison requested was not conducted in the 2024 material.	❌ No proof of the claimed process change; especially important because the substantive equality comparison was still missing from the February policy evidence.
Action 7 – Equity of previous decisions	In progress: previous SERPC decisions where application differed between men and women to be reviewed for equity.	No review, work paper, list of decisions or interim output supplied.	❌ No evidence supplied of progress.
Action 8 – Publication of rationale	In progress: agreement being sought from ICB representatives.	No correspondence, proposed publication framework or decision supplied.	❌
Action 9 – Context for SERPC decisions	In progress: align SERPC work programme with ICB commissioning responsibilities and budgets.	No supporting record supplied.	❌
Action 10 – Committee training	In progress: information sessions planned covering cost-effectiveness, evidence bias, NICE obligations and ethics.	No training materials, invitations, agenda or attendance record supplied.	❌
Action 11 – Patient autonomy / experience	In progress: ethical framework review scheduled for June.	No revised ethical framework or June Governance Group record supplied.	❌
Action 12 – EIA template	In progress: current Equality Impact Assessment template to be reviewed, scheduled for June.	No revised template, review paper or June decision supplied.	❌
Action 13 – Information sharing	In progress: review other regional Terms of Reference and ethical frameworks for shared learning.	No comparative review or related record supplied.	❌
Action 14 – Public consultation	To be progressed: expert advice/communications support to create a lawful, robust consultation process.	No consultation framework or completed process supplied. On 6 May, Broughton expressly acknowledged that the work had not yet been completed and that “there is no formal public consultation programme currently underway.”	🔴 Not merely absent from disclosure: Broughton subsequently confirmed it remained undone.
6 May 2026	Governance Group had discussed public engagement in February and agreed a clearer consultation approach.	No February Governance Group minutes or decision record supplied.	❌
6 May 2026	Further expert advice was being sought on consultation duties.	No advice request, advice received, legal/engagement assessment or resulting record supplied.	❌
6 May 2026	Two consultation principles had been agreed: early stakeholder engagement and early flagging of formal consultation requirements.	No policy, template or process document containing those agreed principles supplied.	❌
6 May 2026	Thames Valley would give me a meaningful opportunity to participate, with this documented in the policy governance record.	No consultation invitation or governance record demonstrating that opportunity supplied.	❌
Post-PHSO review itself	A refreshed report reflecting the PHSO findings was considered in April; comments from the SERPC legal adviser, Thames Valley ICB and SCW then raised “significant concerns”; further work happened in June and Draft v2.2 emerged.	None of the refreshed report, April deliberations, “significant concerns” comments, June deliberations or Draft v2.2 were disclosed. Instead, the ICB labelled the refreshed material “outside scope”.	🔴 The ICB itself confirms that the strongest post-PHSO evidence exists, and nevertheless did not supply it.

Important: “not disclosed” does not automatically mean “never happened”. But this Freedom of Information request specifically asked for evidence that the revised post-Ombudsman policy-development processes had been applied. Where the ICB itself identifies records which supposedly document or evidence that work, their absence from the disclosure is itself highly relevant.

Why is the January 2026 approval paper so important?

Because it shows what the February policy was actually being approved on.

The January Quality Oversight Group paper states that the female sterilisation commissioning position underwent its “full evidence review” in December 2024.

It then lists the supporting documents used for adoption:

• the draft SERPC-04 policy;
• the December 2024 Female Sterilisation Clinical Commissioning Policy review;
• the SERPC-04 Equality Impact Assessment;
• the supporting information for policy adoption;
• and prior-approval forms.

That is the documentary foundation I was actually shown for the February 2026 decision.

The paper acknowledges that the Ombudsman investigation had concluded and says an action plan was underway.

But acknowledgement that an Ombudsman report exists is not the same thing as redoing the evidence, equality, legal, ethical, consultation and decision-making work in light of its findings before adopting the replacement policy.

Indeed, the same January paper places several further governance steps after the proposed approval, including submission of an EQIA to an EQIA panel and consultation with specialist clinicians.

Where is the actual decision approving the policy?

There is another basic problem.

The January document supplied to me says:

“Virtual decision by email requested.”

It asks Quality Oversight Group members to consider approving the policy.

That is evidence of a request for approval.

It is not, by itself, the resulting decision.

I therefore asked for the actual recorded QOG approval or ratification decision: the vote, email decision, confirmation or equivalent record showing that approval occurred and what the decision-makers relied upon.

That was not in the disclosure I received.

What happened to the equality work?

The supplied SERPC Equality Impact Assessment dates from December 2024.

It says no specific patient engagement took place, identifies no missing information, concludes that no changes were necessary, and contains blank fields for the director or decision-maker and date signed.

The January 2026 QOG paper then says that further implementation work should include:

“lead EQIA submission to and approval by EQIA panel”.

So where is that EQIA?

Where is the panel record?

Where is the signed final equality analysis?

And, particularly importantly, where is the post-Ombudsman analysis comparing male and female access to permanent contraception?

Did the ICB actually compare female sterilisation with vasectomy?

The FOI response gives a surprisingly clear answer regarding the 2024 material:

That is particularly important because the Ombudsman had already identified failures in treating equivalent circumstances involving women and men fairly and consistently.

The later 14-point action list then says a review of previous SERPC decisions where application differs between men and women was still “in progress”.

So the question remains:

Where is the documentary evidence that the substantive male-versus-female equality comparison was completed before the February 2026 policy was put into force?

I have not been shown it.

Why does the later April review matter so much?

The ICB's final FOI response confirms that the genuinely refreshed review reflecting the PHSO findings came later.

A refreshed report was presented in April 2026.

After that meeting, comments from the SERPC legal adviser, NHS Thames Valley ICB and the SCW Clinical Policy Implementation team reportedly raised “significant concerns”.

The recommendation was therefore not issued at that point.

It went back for further consideration in June.

A later revised recommendation was then produced.

That matters because Dr Priya Singh subsequently told me that this later recommendation removed the requirement for women to undergo a LARC trial before sterilisation if they did not wish to consent to LARC.

So another obvious question follows:

Why am I challenging the redactions too?

The disclosure problem is not limited to missing documents.

Names and official roles of people participating in healthcare policy-making were redacted under section 40(2).

I am not seeking private addresses or personal contact details.

I am seeking transparency about who participated in decisions affecting access to NHS healthcare.

I have therefore challenged those redactions and asked the ICB to justify why the identities of officials and professional advisers acting in official capacities should remain hidden.

Why are the cost redactions particularly relevant?

Activity, expenditure and cost figures were also blacked out in parts of the disclosure.

That matters because cost and cost-effectiveness have historically been relied upon as part of the justification for limiting women's access to female sterilisation.

Where financial considerations have been used to justify restrictions on healthcare access, there is a strong public-interest reason for being able to scrutinise the numbers and assumptions relied upon.

The disclosure is also internally inconsistent.

Figures hidden in one attachment appear openly in another, including an estimated annual cost impact of £162,000 for BOB, £47,000 for Frimley, 344 admissions, £640,000 expenditure in 2023/24 and an average cost of £1,870.

I have therefore asked the ICB to disclose the underlying activity and cost information unless it can provide a specific and legally sustainable reason for withholding it.

What about the pages marked “out of scope”?

The December 2024 SERPC minutes also contain whole sections removed as “out of scope”, including:

• Fertility Preservation;
• EBI Recommendations for Urology;
• and Retired EBI Statements.

These may ultimately prove unrelated to female sterilisation.

But I am no longer prepared simply to accept entire blocks of a decision-making meeting being hidden while being told they are irrelevant.

I have therefore requested the complete text of those sections, subject only to any specific FOIA exemption the ICB can properly justify.

If they are unrelated, the documents will show that.

Why am I now asking for metadata?

Some of the disclosed records are unsigned, undated, described as drafts, or do not make clear when the version supplied was actually created or finalised.

During the prolonged FOI delay, I specifically asked the ICB to confirm that responsive documents had been preserved in their original form, including their metadata, and that nothing had been altered, destroyed, concealed or retrospectively created.

The ICB answered:

“The ICB can confirm this.”

I have therefore asked them to substantiate that assurance by providing the available creator, creation date, modification date, last-modified-by information and version/edit history for the key documents.

After an FOI response delivered two months beyond its legal deadline, I am no longer prepared simply to accept assurances about document provenance where the underlying metadata can establish the chronology objectively.

Why is this more than an FOI technicality?

Because the Ombudsman had already investigated this organisation's handling of female sterilisation policy.

The findings concerned failures involving evidence, clinical guidance, equality, consultation, transparency, decision rationale and complaint handling.

The ICB then repeatedly said that lessons had been learned.

Dr Nick Broughton said feedback had been documented.

He described a further review timetable.

He said corrective actions had been systematically recorded in a 14-item tracker.

He said equality prompts had been added.

He said decision rationale would be properly recorded.

He said the ethical framework had been brought back into committee decision-making.

He said previous decisions affecting men and women differently would be reviewed.

He described future consultation reforms.

Then I filed an FOI specifically asking for the evidence that these new processes had actually been applied.

And many of the records that should prove those claims were not supplied.

I am not saying that every missing record proves that the action never happened.

I am saying that an organisation previously criticised for poor documentation, transparency and decision-making has once again asked the public to rely on assurances while failing, in its FOI disclosure, to produce much of the documentary evidence that should substantiate those assurances.

How long did the FOI disclosure take?

I submitted FOI-TV-2606-105 on 8 June 2026.

The statutory deadline was 6 July 2026.

NHS Thames Valley ICB did not provide the substantive disclosure until 4 September 2026.

The ICB has now expressly accepted that the statutory deadline was seriously missed and that there was no legal authority for the replacement date it had proposed.

By the time I received the documents, I had spent months chasing a disclosure about whether the NHS had actually corrected failures already identified by an Ombudsman investigation.

And once the documents finally arrived, the post-Ombudsman audit trail was still largely missing.

What have I now asked NHS Thames Valley ICB to provide?

I have asked the ICB to complete the disclosure by providing or accounting for the records it has itself described, including:

• the documented February feedback on the PHSO findings;
• the February SERPC and SERGG records;
• the updated Terms of Reference;
• the April refreshed review report;
• the April SERPC minutes;
• the 14-item action tracker;
• records showing completion of the actions marked complete;
• the legal, Thames Valley and SCW comments which reportedly raised “significant concerns”;
• the actual QOG approval or ratification record;
• any completed EQIA and EQIA-panel approval record;
• the challenged redacted information;
• and the preserved metadata for the key policy-development records.

What happens next?

I have given NHS Thames Valley ICB until the end of Tuesday 15 September 2026 to provide the outstanding records and corrected disclosure or explain, item by item, why information is not held, outside scope or legally exempt.

This is not a new statutory deadline.

The statutory deadline expired on 6 July 2026.

It is simply the final practical opportunity I am giving the organisation to complete a disclosure that is already substantially overdue.

If the ICB does not provide the records, I will proceed using the evidence already available through the Information Commissioner's Office, NHS England and the other external accountability and scrutiny routes already underway.

Where can I read the evidence?

You can read the original Freedom of Information request, the delayed disclosure, the ICB's responses, my challenge to the omissions and redactions, the Ombudsman material and the wider documentary history in my Evidence Folder.

I do not expect anyone to take my interpretation on trust.

Read what the NHS said it had done. Read what it actually disclosed. Compare the two. Then make up your own mind.

Two Vasectomy Pathways FOIs Later: Will NHS Thames Valley ICB Finally Show the Evidence?

Why am I asking about NHS-funded vasectomy again?

This follows directly from my previous investigation into the difference between access to male and female permanent contraception.

I discovered that NHS-funded vasectomy services can be delivered through private or independent providers and that direct-access or self-referral arrangements have existed or been developed for men.

At the same time, women seeking permanent contraception have faced a very different history of restrictions, approval requirements and contraceptive gatekeeping.

I wanted to know how that difference had been commissioned, governed and equality-assessed.

You can read the full background here:

What happened to the first vasectomy FOI?

My first request, TV-2607-192, was deliberately broad because I wanted to understand the commissioning history, providers, referral pathways, safeguards and equality assessment surrounding NHS-funded vasectomy.

NHS Thames Valley ICB refused it under Section 12 of the Freedom of Information Act, saying the work required would exceed the statutory cost limit.

I then asked the ICB to fulfil its duty under Section 16 and help me formulate a narrower request that it could answer.

I dramatically reduced what I was asking for.

The ICB nevertheless said it could identify no meaningful refinement.

So I did the refining myself.

How narrow is the second FOI?

On 3 September 2026, I submitted a completely new Freedom of Information request.

I expressly removed:

• historic and expired vasectomy arrangements;
• previous providers;
• historical pathway versions;
• procurement history;
• historic correspondence;
• the original search back to 2017;
• and any request for the ICB to create a new analysis.

I am now asking for only two categories of existing records.

First: the current documents showing how patients presently access NHS-funded vasectomy under relevant former BOB ICB arrangements that remain operative, and any genuinely new Thames Valley-wide arrangements.

Second: the current or most recent recorded evidence showing how equality duties were considered when those arrangements were commissioned, continued or adopted.

That includes NHS-funded services delivered through private or independent providers.

If no equality evidence exists, I have simply asked the ICB to say so.

Why does the equality evidence matter?

Because this is not just a question about where men book a vasectomy.

The underlying question is whether NHS Thames Valley ICB has properly considered the difference between how men and women access permanent contraception.

If men can receive NHS-funded permanent contraception through comparatively straightforward private-provider pathways while women have historically been subjected to substantially more gatekeeping, then I want to see the evidence showing how that difference was assessed.

Not another reassurance.

The records.

Even the acknowledgement had to be chased

The new request was submitted on 3 September 2026.

Seven days later, on 10 September 2026, I still had no acknowledgement and no reference number.

So I chased it.

On 12 September 2026, NHS Thames Valley ICB finally confirmed that the request had been logged and gave it the reference:

The late acknowledgement does not restart the statutory clock.

The request was submitted on 3 September.

When does NHS Thames Valley ICB have to respond?

Under the Freedom of Information Act, public authorities ordinarily have to respond promptly and no later than the twentieth working day following receipt of a valid request.

For this request, that gives NHS Thames Valley ICB a statutory deadline of:

So what am I waiting to see?

At this point, the test is very simple.

I want to see whether NHS Thames Valley ICB will:

1. meet the statutory deadline;
2. provide the current vasectomy pathway documents;
3. provide the equality evidence it holds;
4. clearly confirm if particular records do not exist;
5. and provide a substantive response rather than creating another transparency battle.

The original request was broad.

This one is not.

I have reduced it to the records that should be closest to hand if NHS Thames Valley ICB is currently commissioning, funding or administering these services.

So this time, I am leaving the question here publicly before the deadline passes.

What happens next?

I am not going to keep expanding this post every time another email arrives.

This is simply a marker of where the investigation stands now.

When NHS Thames Valley ICB responds — or if the statutory deadline passes without a lawful response — I will publish the next part separately.

That way, there is a clear public record of what I asked, when I asked it and what the ICB was required to do next.

You can follow the wider chronology on The Timeline, and the underlying correspondence is available through my Evidence Folder.

I Took My NHS Sterilisation Battle to Health Scrutiny. What Can They Actually Do?

Why did I approach a council committee about an NHS policy?

By July 2026, my dispute with the NHS had long stopped being simply about what happened to me in 2022.

The Parliamentary and Health Service Ombudsman had already investigated my case and found serious problems with the way the previous female sterilisation policy had been developed and applied. The ICB had subsequently replaced that policy and publicly presented the problem as addressed. Yet when I examined the replacement policy, I found that women still face restrictions that men seeking vasectomy did not.

At the same time, I had been trying to obtain the evidence showing how that replacement policy had actually been developed: its equality analysis, evidence base, approval records and reasoning. My Freedom of Information request had gone overdue, an Internal Review later confirmed that the statutory deadline had been breached, and the information was still not being disclosed.

That combination mattered. I was no longer asking, "Was the decision in my individual case wrong?" I was asking whether a healthcare policy affecting a population of women had been developed fairly, lawfully, transparently and on proper evidence — and whether an NHS organisation that had already been criticised by the Ombudsman had genuinely corrected the underlying problem.

That is precisely the kind of question health scrutiny exists to examine.

So what is a Health Overview and Scrutiny Committee?

Health scrutiny is part of local democratic accountability. In Oxfordshire, the Joint Health Overview and Scrutiny Committee looks at NHS and other health services provided within the county. Unlike most council scrutiny committees, which primarily examine what the council itself is doing, health scrutiny specifically gives elected councillors a mechanism for examining organisations outside the council, particularly NHS bodies.

Government guidance describes the primary purpose of health scrutiny as improving the health of local people and ensuring that their needs are taken into account when health services are commissioned, developed and delivered. It is also an important means through which elected councillors can represent their communities and hold NHS bodies accountable.

That is why I approached them.

What can they actually make the NHS do?

This is where things become important, because "scrutiny" can sound considerably softer than it actually is.

Under the Local Authority (Public Health, Health and Wellbeing Boards and Health Scrutiny) Regulations 2013, health scrutiny bodies have statutory powers to review and scrutinise matters concerning the planning, provision and operation of NHS services. That can include how services are commissioned, how policies operate and even the finances behind healthcare decisions.

They can also require certain NHS bodies — including Integrated Care Boards — to provide information that is reasonably necessary for scrutiny. They can require members and employees of NHS bodies to attend and answer questions. They can hear evidence from patients, clinicians and other organisations, examine competing evidence and conduct their work publicly.

Most importantly, they can produce formal reports and recommendations. If they request a response to those recommendations, the relevant NHS body has a statutory duty to respond in writing within 28 days.

For my case, that creates possibilities that are very different from me emailing the ICB for the forty-somethingth time asking them to explain themselves. Councillors could ask the ICB why women and men have different routes to permanent contraception. They could request the evidence behind the female sterilisation criteria. They could question relevant ICB leaders publicly. They could ask how the Ombudsman's findings were implemented, what equality analysis was conducted, and why the current policy should be considered equitable.

But they cannot simply overturn the policy

This is also not a court.

A Health Overview and Scrutiny Committee cannot look at the policy one afternoon, declare it unlawful and order NHS Thames Valley ICB to replace it the next morning. Its recommendations do not function like a court order.

In that sense, there is an uncomfortable similarity with my experience of the Ombudsman. The Ombudsman can investigate maladministration, reach findings and recommend remedies, but it does not normally issue legally enforceable judgments in the way a court does.

Health scrutiny operates differently, but it also largely relies on accountability rather than direct command. Its strength is that the NHS can be required to provide information, appear publicly, answer questions and formally respond to conclusions reached by democratically elected representatives.

That matters because institutional problems survive surprisingly well in private correspondence. They become considerably harder to dismiss when questions, evidence, answers and recommendations enter a public record.

Getting the issue onto the agenda was a battle of its own

I first contacted the Committee on 23 July 2026 with a detailed written request for scrutiny.

On 7 August, Health Scrutiny Officer Dr Omid Nouri confirmed that he had discussed the matter with the Chair and that female sterilisation and its eligibility criteria were indeed within the Committee's remit. Initially, however, I was directed towards the public-meeting process: I could attend and make a statement of up to three minutes.

I pushed back. Oxfordshire's own scrutiny information allows members of the public to suggest issues for scrutiny, and this was not something that could meaningfully be reduced to three minutes. It involved years of correspondence, an Ombudsman investigation, policy development, equality questions, FOI failures and governance concerns.

On 12 August, I was told my written request would be taken back to the Chair, potentially with the wider Committee involved. The possible outcomes included asking the ICB for a written statement, taking the matter into the Committee's work programme, or deciding not to investigate it.

Then, on 11 September 2026, the answer arrived.

The Committee has decided to hold a public item on Women's Health, most likely at its meeting on 11 February 2027, and I have been told that female sterilisation will be included within it.

And now I put another date in the calendar

11 February 2027 is exactly five months from the day I received that email.

So I have put another pin in my calendar.

And increasingly, that is what this battle looks like. Remember this deadline. Chase that response. Give them until this date. Escalate if nothing arrives. Come back to this person in three weeks. Check whether this review happened. Prepare for February.

There is something profoundly wrong with a healthcare accountability system that can require an ordinary person to become their own investigator, records manager, legal researcher, complaints officer and project manager simply to establish what happened and whether anything has actually changed.

I should never have needed to learn how all of these mechanisms work.

But since I have had to learn, I will document them — because understanding where power sits, what each organisation can actually do, and where its power stops is becoming as much a part of this story as the sterilisation policy itself.

You can follow the documentary trail, including my correspondence with the scrutiny team and the wider evidence behind this case, in the Evidence Folder.

Sources and further reading

• Department of Health and Social Care, Local authority health scrutiny, statutory framework and guidance on the powers of health scrutiny bodies.
• Department of Health and Social Care, Local Government Association and Centre for Governance and Scrutiny, Health Overview and Scrutiny Committee Principles.
• The Local Authority (Public Health, Health and Wellbeing Boards and Health Scrutiny) Regulations 2013.
• Oxfordshire County Council, Scrutiny at Oxfordshire County Council, including the role of the Joint Health Overview and Scrutiny Committee.
• My correspondence with Oxfordshire Joint Health Overview and Scrutiny Committee, 23 July–11 September 2026, available through the Evidence Folder.

Disclosure and scope: This article combines documented facts with my own analysis as a social psychologist and as the patient whose complaint about access to female sterilisation in Oxfordshire exposed serious failures in NHS policy-making and complaint handling. Where I am offering an interpretation rather than reporting an established causal fact, I say so explicitly.

As a social psychologist, I spend a great deal of time thinking about how ideas spread. We tend to imagine social contagion as something obvious: a slogan goes viral, a political movement suddenly becomes fashionable, or a set of talking points appears everywhere at once. In reality, belief systems often travel much more quietly. They move through professional networks, think tanks, legal arguments, conferences, political relationships, religious communities, donor networks, media framing and repeated language that slowly makes one way of seeing the world feel normal.

That is one reason I have become increasingly concerned by what is happening to reproductive rights in the United States. Since the US Supreme Court overturned Roe v Wade in 2022, abortion access has become dramatically more dependent on where a woman lives. As of September 2026, the Guttmacher Institute reports that 13 US states have total abortion bans in effect and another 28 have gestational bans. The second Trump administration has also reinstated the Mexico City Policy and rescinded Biden-era executive actions intended to protect access to reproductive healthcare. Whatever one's personal views on abortion, this is plainly a large-scale political reorganisation of reproductive healthcare.

Britain is not America. Our legal system is different, our healthcare system is different, and public attitudes are different. But Britain and the United States have also spent more than 80 years describing their relationship as uniquely close. British governments call it the “special relationship”; the US government has described the UK as its closest ally. That closeness is not confined to defence. Ideas, campaign methods, legal strategies, political personnel, philanthropy and culture move across the Atlantic with unusual ease.

So when a well-funded US legal movement that helped shape the American reproductive-rights battles establishes a London presence, increases its UK spending, briefs MPs, supports litigation and builds relationships inside Westminster, I think the right question is not, “Are we becoming America tomorrow?” The right question is: what ideas are being normalised today, who is paying to normalise them, and what happens if we only notice after institutional practice has already shifted?

What does “social contagion” have to do with reproductive rights?

Social contagion does not mean that one country mechanically copies another. It means attitudes, narratives and behavioural models can spread through networks. Political movements learn from each other. Campaigners borrow language that has worked elsewhere. Legal organisations test arguments in one jurisdiction and adapt them to another. Politicians observe which issues mobilise supporters. Media ecosystems repeat frames until they become familiar.

In the United States, the abortion debate was not transformed overnight. It was the result of decades of organising: litigation, judicial appointments, state legislation, donor funding, activist mobilisation, religious campaigning and the construction of an intellectual and legal infrastructure capable of turning a long-term ideological objective into public policy. Dobbs v Jackson Women's Health Organization was the legal endpoint of a much longer political process.

This matters because one of the organisations embedded in that US legal infrastructure — Alliance Defending Freedom, or ADF — now has a substantial British operation.

Who is Alliance Defending Freedom, and why does its UK growth matter?

Alliance Defending Freedom is a US-founded Christian legal advocacy organisation. Its American operation is large: according to its 2024 US tax filing, reported by ProPublica's Nonprofit Explorer, it had revenue of approximately $110.7 million and expenditure of approximately $106.4 million. ADF has participated in major US litigation concerning abortion, religious liberty and LGBT rights. It was involved in the legal movement around Dobbs, the Supreme Court decision that removed the federal constitutional right to abortion.

ADF's international arm has built a presence in European centres of political and legal power, including London, Brussels, Strasbourg, Geneva and Vienna. Its UK entity, ADF International (UK), is a registered charity and company. The Charity Commission describes its charitable purpose as advancing Christianity and promoting Christian principles and ethics. 

The financial trajectory is notable. ADF International UK's Charity Commission entry shows income of £1,468,307 and expenditure of £1,404,402 for the year ending 30 June 2025. The Guardian had previously reported that its spending rose from roughly £392,000 in 2020 to almost £1 million in the year to June 2023. This is no longer a tiny overseas campaign office operating at the edge of British political life. It is a seven-figure organisation with staff, lawyers, parliamentary relationships and an explicit advocacy strategy.

What does ADF say it is doing?

ADF presents its work as human-rights advocacy centred on religious freedom, freedom of speech, parental rights and protection of life. In Britain it has repeatedly framed disputes around abortion-clinic “buffer zones” or “safe access zones” as questions of free expression and religious freedom. It has supported or represented people accused of breaching restrictions around abortion clinics, and it has opposed efforts to decriminalise abortion.

That framing deserves to be represented accurately. ADF does not publicly describe itself as an organisation trying to import an American culture war. It says it is defending fundamental freedoms and the right to life. People who share those values may regard its work as principled civil-liberties advocacy.

Critics see something different: a sophisticated legal organisation using rights-based language to pursue an agenda that has historically included restricting abortion access and opposing LGBT rights. Those concerns are not based only on rhetoric. They arise from ADF's litigation record, its US political relationships and its expanding European presence.

How close has ADF UK come to British political power?

The answer is: close enough that it deserves serious public attention.

In 2024, The Guardian reported that ADF International UK had been producing policy briefings and legal analysis for MPs, including ahead of votes concerning buffer zones around abortion clinics. The newspaper also reported that ADF had been appointed as a stakeholder to a parliamentary group concerning freedom of religion or belief, and that in September 2023 it paid travel and accommodation costs for Fiona Bruce MP, then the Prime Minister's Special Envoy for Freedom of Religion or Belief, to attend a conference.

In April 2025, Baroness Bennett asked the Government what assessment it had made of the impact of lobbying by overseas-funded organisations such as ADF on UK human rights and democracy. The Government did not announce a specific investigation into ADF. Its answer instead pointed to ministerial transparency rules, parliamentary registers and rules governing all-party parliamentary groups.

That response is revealing in its own way. The existence of foreign-linked ideological advocacy inside Westminster is not hypothetical; it has become sufficiently visible to generate parliamentary questions about transparency and influence.

Is ADF the whole story?

No. Focusing exclusively on ADF would make the picture misleadingly simple. Britain's anti-abortion movement includes longstanding domestic organisations, parliamentary networks, religious groups, campaign organisations and newer transnational actors. Some are primarily British and funded largely through British supporters. Some have international ideological or organisational connections. They do not all share the same tactics or every policy position.

Right To Life UK: a direct parliamentary bridge

Right To Life UK is a British registered charity focused on abortion, assisted suicide and embryo research. It describes its mission as protecting human life from conception to natural death and says it works through education, politics, media and a network of supporters across the UK.

Its political role is unusually concrete. The official Parliamentary Register records that Right To Life UK acts as secretariat to the All-Party Parliamentary Pro-Life Group. As of February 2026, the APPG was chaired by DUP MP Carla Lockhart, with Baroness Eaton, Sir Desmond Swayne and Baroness Ritchie of Downpatrick among its officers. Right To Life UK itself says its public-affairs team supplies research, briefings and policy analysis to MPs and peers and has direct relationships with parliamentarians across parties.

Its financial scale is also significant. Charity Commission figures for the year ending March 2025 record income of £1,164,156 and expenditure of £1,231,188. Right To Life UK says it receives no government funding and is funded by supporter donations.

This is important because influence does not require secret meetings or conspiracies. An organisation that drafts briefings, provides an APPG secretariat, mobilises constituents to contact MPs, tracks voting records and maintains relationships with parliamentarians is describing ordinary, organised political advocacy. The democratic question is not whether advocacy should exist. Of course it should. The question is whether the public understands who is doing it, how well resourced they are, and how their goals fit into a broader ecosystem.

SPUC, 40 Days for Life and clinic-focused campaigning

The Society for the Protection of Unborn Children (SPUC) is one of Britain's oldest anti-abortion organisations. It has campaigned for decades against abortion and on related bioethical issues. Separately, the US-originated 40 Days for Life model — prayer vigils and activism around abortion clinics — has been adopted in Britain. OpenDemocracy has reported that British anti-abortion organiser Robert Colquhoun described being inspired by US counterparts and was credited by 40 Days for Life with helping export the model into the UK.

Again, the point is not that every British campaign is controlled from America. The more interesting and better-supported conclusion is that tactics, legal theories and movement know-how cross borders. Domestic organisations can remain domestically run while still participating in an international political culture.

How much money is moving through the wider European “anti-rights” ecosystem?

We should be careful with labels here. “Anti-rights” and “anti-gender” are terms used by organisations that monitor movements opposing abortion rights, LGBT rights, sex education and some gender-equality policies. The groups being described often reject those labels and instead describe themselves as pro-life, pro-family or defenders of religious freedom.

With that caveat, the scale documented by the European Parliamentary Forum for Sexual and Reproductive Rights (EPF) is substantial. Its 2021 report, Tip of the Iceberg, identified approximately $707 million in spending by a sample of organisations active across Europe between 2009 and 2018, including about $81 million originating from US actors. EPF's 2025 follow-up, The Next Wave, reported $1.18 billion in spending by anti-rights and anti-gender initiatives in Europe between 2019 and 2023.

These numbers do not mean that $1.18 billion was spent on British abortion lobbying, nor that all organisations in the dataset have identical aims. They do show that the European political environment around sexuality, reproduction and gender now includes a large, professionalised, transnational advocacy sector.

Why does the American example matter now?

Because the American movement demonstrates what long-term infrastructure can accomplish.

In June 2022, the Supreme Court decided Dobbs and overturned the constitutional framework created by Roe v Wade. By September 2026, Guttmacher counted 13 states with total abortion bans and 28 more with gestational bans. The legal conflict has also moved to medication abortion. Just this month, a federal appeals court has been considering another attempt by Republican-led states to restrict access to mifepristone, the drug used in most US abortions.

At federal level, President Trump in January 2025 ordered enforcement of the Hyde Amendment as administration policy and revoked two Biden executive orders designed to protect access to reproductive healthcare. On the same day, he reinstated the Mexico City Policy for overseas health assistance.

None of those developments proves that Britain will follow the same path. But they demonstrate that reproductive rights that appear politically settled can become unsettled when sufficiently organised movements acquire legal, political and institutional leverage.

But what does any of this have to do with female sterilisation?

This is where I want to be exceptionally clear.

I have found no evidence that ADF, Right To Life UK, SPUC or any other anti-abortion organisation caused the NHS restriction that affected my access to female sterilisation. I have also found no evidence that ADF lobbied NHS England to weaken national wording about the funding of female sterilisation.

I will not manufacture that connection merely because it would make a dramatic story.

My concern is about something broader: the political environment in which women's reproductive autonomy is interpreted. Reproductive freedom does not begin and end with abortion. It includes access to contraception, informed consent, the ability to continue a pregnancy, the ability to end one within the law, fertility care, and — for adults who do not want children — the ability to make a considered permanent choice not to become pregnant.

When a political culture becomes increasingly comfortable with the idea that institutions may override women's reproductive preferences “for their own good”, “for the unborn”, “because they may regret it”, “because another method is preferable”, or because access should depend on local policy, I pay attention. The arguments are not identical, but the underlying question of who gets final authority over reproductive decisions is connected.

What changed on the NHS website — and why do I consider it monumental?

The current NHS England information on female sterilisation says:

“Sterilisation may be available free on the NHS, or you may need to pay for your treatment.”

Read that next to the NHS's general contraception information, which states that contraception services are free and confidential on the NHS, and next to the NHS Constitution's principle that access to NHS services is based on clinical need rather than ability to pay.

The wording matters because female sterilisation is itself listed by the NHS as a method of contraception. It is more than 99% effective and does not affect hormones. Yet the national patient-facing page now explicitly tells women that this particular contraceptive option may not be funded where they live.

Older NHS-facing and NHS-derived information presented contraception much more straightforwardly as free on the NHS, and Sexual Health London material reviewed in 2020 stated directly that female sterilisation was available free on the NHS. The present national wording is therefore materially weaker than the expectation historically created around NHS contraception.

For me, this is not a cosmetic website edit. It is a public acknowledgement of a postcode lottery.

What does a postcode lottery look like in practice?

It means two women with the same reproductive wishes, similar clinical circumstances and equal capacity to provide informed consent may encounter different pathways because they live under different commissioners. One may be referred. Another may be required to try long-acting reversible contraception first. Another may discover that the service is not routinely commissioned. Another may be told she can pay privately.

That is precisely the kind of local variation that my own case forced me to confront. The Oxfordshire policy applied to me required women seeking sterilisation to use long-acting reversible contraception first, unless exceptions applied. My complaint was not simply that I disliked the answer. I challenged the evidential, equality and governance basis of a policy that restricted a permanent reproductive choice.

The Parliamentary and Health Service Ombudsman later found failures in the way the policy and my complaint had been handled. Yet the broader problem remains: a national health service can still allow local commissioning decisions to determine whether a fundamental reproductive option is practically available.

Is local commissioning automatically a violation of women's rights?

No. The NHS has finite resources, and Integrated Care Boards make local commissioning decisions across many services. Different clinical needs and local service structures can legitimately produce variation.

But that cannot be the end of the conversation. NHS England and ICBs also have statutory duties concerning equality and health inequalities. The NHS Constitution states that the service should be comprehensive, available to all, and that patients should not be refused access on unreasonable grounds. It also says care should reflect patients' needs and preferences.

So the real question is not whether any local variation may exist. It is: how much variation is acceptable when the service in question concerns bodily autonomy and reproductive decision-making, and what evidence must commissioners produce before restricting it?

Could Britain lose reproductive rights without ever announcing that it is doing so?

That is the question that worries me most.

Rights do not always disappear through a single dramatic Act of Parliament. Sometimes they become harder to exercise. A service stops being routinely commissioned. Eligibility criteria narrow. Waiting lists become prohibitive. A procedure remains technically legal but practically inaccessible. National wording shifts from “available” to “may be available”. Patients are redirected to private payment. The formal right survives while meaningful access erodes.

From a social-psychological perspective, this is also how norm change can occur: not necessarily by persuading everyone that a right should disappear, but by gradually changing what people accept as normal.

That is why I continue pressing the NHS for accountability long after my own individual complaint could have ended. I do not need to prove that an American organisation wrote an Oxfordshire sterilisation policy in order to be concerned about the wider environment. I need to show, carefully and document by document, where women's choices are being narrowed, who is lobbying political institutions on reproductive issues, what ideas are crossing borders, and whether the safeguards that are meant to protect equality and patient autonomy are actually working.

So, is Britain importing America's reproductive-rights culture war?

Not wholesale. Not inevitably. And not in the simplistic sense that Washington gives instructions and Westminster follows them.

But there is strong evidence that American organisations, money, legal strategies and campaign models are operating inside the British and European political environment. There is strong evidence that ADF's UK spending and Westminster activity have grown. There is strong evidence of organised parliamentary advocacy by domestic anti-abortion organisations. And there is undeniable evidence that the American reproductive-rights settlement once regarded as constitutionally secure was dismantled after decades of organised political and legal work.

For me, those facts justify vigilance, not conspiracy.

And when, at the same time, the national NHS website tells women that permanent contraception “may” be funded or they “may” have to pay, I think we should ask harder questions about what reproductive freedom actually means in Britain.

For a closer investigation of the organisations, funding, parliamentary relationships, litigation strategies and political machinery behind this movement, read my companion article: The American Anti-Abortion Movement Is Spending Money in Britain. What Does It Want?

References and further reading

1. NHS. Finding out about female sterilisation. Current NHS England patient information; reviewed 14 February 2024.
2. NHS. Where to get contraception. NHS patient information stating that contraception services are free and confidential on the NHS.
3. Department of Health and Social Care. The NHS Constitution for England and accompanying handbook.
4. Supreme Court of the United States / Cornell Legal Information Institute. Dobbs v Jackson Women's Health Organization, 597 U.S. 215 (2022).
5. Guttmacher Institute. State Bans on Abortion Throughout Pregnancy. Updated September 2026.
6. The White House. Enforcing the Hyde Amendment. Executive Order, 24 January 2025.
7. The White House. Memorandum on the Mexico City Policy. 24 January 2025.
8. UK Parliament House of Commons Library. UK-US bilateral relationship. 31 January 2025.
9. Charity Commission for England and Wales. ADF International (UK), charity no. 1173195. Accounts and annual returns, including year ending 30 June 2025.
10. ProPublica Nonprofit Explorer. Alliance Defending Freedom. US Form 990 financial data for fiscal year ending June 2024.
11. The Guardian, Shanti Das. ‘Extreme’ US anti-abortion group ramps up lobbying in Westminster. 6 April 2024.
12. The Guardian. US anti-abortion group expands campaign in UK. 2 April 2025.
13. UK Parliament. Written Question HL6542, Baroness Bennett of Manor Castle; answered 28 April 2025.
14. UK Parliament. Register of All-Party Parliamentary Groups: Pro-Life. 23 February 2026 edition.
15. Charity Commission for England and Wales. The Right To Life Charitable Trust, charity no. 1099319. Accounts for year ending 31 March 2025.
16. Right To Life UK. About us and All-Party Parliamentary Pro-Life Group.
17. European Parliamentary Forum for Sexual & Reproductive Rights. Tip of the Iceberg: Religious Extremist Funders against Human Rights for Sexuality & Reproductive Health in Europe. 2021.
18. European Parliamentary Forum for Sexual & Reproductive Rights. The Next Wave: How Religious Extremism Is Reclaiming Power. 2025.
19. openDemocracy. Revealed: Files expose ‘culture war’ ties between anti-abortion groups and Brexit. 2021.
20. Sexual Health London. Female sterilisation. Clinical information reviewed December 2020.

Editorial note: I distinguish throughout between documented lobbying and funding, criticism made by reproductive-rights organisations, and my own interpretation of the risks posed by gradual restrictions on reproductive autonomy. I have found no evidence that ADF or another anti-abortion organisation caused the NHS female-sterilisation commissioning restriction discussed in my case.

Disclosure and scope: I am writing this as a social psychologist and as a woman whose challenge to an NHS female-sterilisation policy became a prolonged accountability battle. This is an evidence-led investigation. It does not allege that the organisations discussed below caused the NHS policy in my case; where no such evidence exists, I say so.

As a social psychologist, I am fascinated by the moment when an idea stops looking fringe and starts looking normal. Social contagion is often misunderstood as imitation: one person copies another, one country copies another. But ideological contagion is usually more sophisticated. A belief travels with a network. It gains lawyers, donors, spokespeople, parliamentary contacts, research papers, campaign language, sympathetic media platforms and repeated opportunities to define what the argument is supposedly “about”.

This is why the United States matters to me when I look at women's reproductive rights in Britain.

America and Britain have what both governments still call a “special relationship”. The two states cooperate unusually closely in diplomacy, security, economics, technology and culture. Their political movements also watch each other. Campaign tactics cross the Atlantic. Think tanks quote one another. Lawyers share arguments. Conferences connect activists. Donors fund international work. Language developed in one political system can become useful in another.

At the same time, the United States has undergone one of the most dramatic reversals of reproductive-rights protection in the modern democratic world. Roe v Wade was overturned in 2022. By September 2026, 13 states had total abortion bans and 28 more had gestational bans. Federal policy under President Trump has again moved in an anti-abortion direction, including reinstatement of the Mexico City Policy and reversal of Biden-era reproductive-health executive actions.

So I wanted to ask a more forensic question than “Could this happen here?”

Who is already working here, how much money is involved, who has access to Parliament, which legal and political strategies are being used, and what do these organisations themselves say they want?

This is the narrower companion to my broader article, Is Britain Importing America's Reproductive-Rights Culture War?, which looks at social contagion, the US-UK relationship and why I connect this political environment to vigilance over women's NHS reproductive choices.

Start with the money: how large is ADF's operation?

Alliance Defending Freedom began in the United States and has become a major Christian legal advocacy organisation. Its US financial scale alone makes it different from the picture many British readers may have of “pro-life activism” as a collection of church volunteers and local campaigners.

ProPublica's Nonprofit Explorer reports that Alliance Defending Freedom's US Form 990 for the fiscal year ending June 2024 recorded revenue of $110,713,980, expenditure of $106,394,230 and net assets of roughly $90.2 million. More than $103 million of its revenue was reported as contributions.

ADF's international operation has offices in strategic European and international centres. The UK entity was incorporated in 2015 and registered with the Charity Commission in 2017. Its registered charitable objects are to advance Christianity by promoting Christian principles and ethics and supporting Christians to live and worship in accordance with them.

The British financial figures have climbed sharply. The Charity Commission records ADF International UK income of £1,468,307 for the year ending 30 June 2025, of which approximately £1.41 million was donations and legacies. Expenditure was £1,404,402, with approximately £1.39 million recorded as charitable expenditure.

For perspective, The Guardian reported that its expenditure was about £392,556 in 2020 and nearly £1 million by the year ending June 2023. That is a substantial expansion in a short period.

Where does ADF UK's money come from?

This is where transparency becomes complicated.

Charity Commission accounts tell the public how much the UK charity receives and spends, and the broad accounting categories involved. They do not provide a public list of every individual donor. ADF in the United States has defended donor privacy in litigation and does not publish a comprehensive donor list. Critics therefore use the phrase “dark money” when discussing parts of the US Christian-right funding ecosystem: not necessarily because the money is illegal, but because the original private sources can be difficult for the public to identify.

It is important not to overstate what that means. A lack of public donor names is not proof of wrongdoing. Charities and advocacy organisations across the political spectrum may lawfully protect donor privacy. The public-interest issue is different: when an organisation is trying to influence law and policy in another country, how much should citizens be able to know about the financial interests sustaining that influence?

That question has been asked at European level for years. The European Parliamentary Forum for Sexual and Reproductive Rights reported in 2021 that it had identified $707.2 million in spending by 54 organisations associated with “anti-gender” activity across Europe from 2009 to 2018, including $81.3 million from US-based actors. Its 2025 report said spending across a larger anti-rights ecosystem totalled $1.18 billion between 2019 and 2023.

Those are advocacy-sector estimates and should be read as such. They include organisations working on a range of issues beyond abortion. They nevertheless establish something important: organised opposition to sexual and reproductive rights in Europe is not financially marginal.

What does ADF actually want?

To answer fairly, start with ADF's own framing.

ADF describes itself as defending fundamental freedoms, especially religious freedom and freedom of expression, and protecting life. Its UK legal work frequently focuses on the ability of Christians to express beliefs in public or act according to conscience. Around abortion, it has opposed decriminalisation and challenged or criticised restrictions on speech and prayer near abortion clinics.

That civil-liberties framing is politically powerful because it changes the apparent question. Instead of “Should campaigners be allowed to confront or influence women entering abortion services?”, the issue becomes “Should the state criminalise silent prayer?” Instead of “Should abortion law be liberalised?”, it becomes “Should unborn life lose legal protection?”

This is not unique to ADF. Successful political advocacy often depends on selecting the moral frame through which everyone else is forced to argue.

Why do critics focus on ADF's American record?

Because the organisation's US legal work places its British arguments in a larger context. ADF was part of the legal ecosystem that spent years challenging abortion rights and participated in the Dobbs litigation that ultimately overturned Roe. It has also litigated extensively on LGBT rights, contraception-related employer mandates and religious exemptions.

Critics therefore argue that apparently narrow British free-speech cases should not be viewed in isolation from the organisation's wider strategic goals. ADF rejects characterisations of itself as extremist and presents its work as principled human-rights advocacy.

For readers, the responsible conclusion is not that every ADF case is secretly “about” banning abortion. It is that an organisation's full litigation history is relevant context when assessing the long-term policy direction of its advocacy.

What is ADF doing in Westminster?

ADF's own annual-report language and investigative reporting indicate a deliberate focus on decision-makers. The Guardian reported in 2024 that the organisation had sought to engage “significant decision-makers” and had provided briefing material and legal analysis to MPs before votes on buffer zones around abortion clinics.

It had also become a stakeholder in parliamentary work on freedom of religion or belief. In 2023, it paid travel and hotel costs for Fiona Bruce MP, then the Prime Minister's Special Envoy for Freedom of Religion or Belief, to attend a conference. The relevant point is not that paying declared travel expenses proves improper influence. It does not. The point is that the organisation had reached a level of political proximity where such interactions occurred.

By April 2025, the issue had reached the House of Lords. Baroness Bennett asked the Government what assessment it had made of the impact on democracy and human rights of lobbying by overseas-funded groups “such as the Alliance Defending Freedom”. The Cabinet Office response stressed existing transparency mechanisms rather than offering a substantive assessment of ADF's impact.

Who else has structured access to Parliament?

Right To Life UK provides perhaps the clearest example of organised domestic anti-abortion access.

The official parliamentary register states that Right To Life UK acts as secretariat to the All-Party Parliamentary Pro-Life Group. In February 2026, the APPG listed Carla Lockhart MP as chair and registered contact, with Baroness Eaton as co-chair and Sir Desmond Swayne and Baroness Ritchie as officers.

Right To Life UK's own website is explicit about what this relationship is for. It says its public-affairs team provides research, briefings and expert policy analysis to MPs and peers, builds direct relationships with parliamentarians and uses campaign tools enabling supporters to contact their MPs with pro-life messaging. It also operates a voting-record platform showing where MPs stand on “life issues”.

This is lobbying in the broad democratic sense of organised efforts to influence representatives, even though UK law uses narrower technical definitions for some lobbying regulation. It is visible, structured and ongoing.

The Charity Commission records income of £1,164,156 and expenditure of £1,231,188 for the Right To Life Charitable Trust in the year ending March 2025. The organisation says it receives no government funding and depends on supporter donations.

What policies are these organisations pushing?

There is not one single manifesto shared by every anti-abortion organisation. But several recurring objectives are visible.

1. Prevent further liberalisation of abortion law

Right To Life UK and ADF have both opposed moves that would decriminalise aspects of abortion law. Right To Life UK routinely mobilises supporters around parliamentary amendments and votes, urging them to contact MPs. Its stated mission is to protect human life from conception.

2. Preserve or expand legal recognition of fetal interests

Campaign groups support amendments that would narrow circumstances in which abortion is lawful or change gestational limits. Right To Life UK has, for example, produced parliamentary briefings seeking equalisation of the abortion time limit for pregnancies involving serious fetal disability.

3. Contest buffer zones and safe-access zones around clinics

ADF has made this one of its most visible UK legal fronts. Supporters frame the issue around prayer and speech. Abortion providers and reproductive-rights organisations frame buffer zones as protection for patients and staff from harassment, intimidation and unwanted influence at a medically and emotionally sensitive moment.

Both sets of rights can be described sincerely. The policy conflict lies in where society draws the boundary between political expression and protected access to healthcare.

4. Strengthen conscience protections

Christian legal organisations often argue that doctors, nurses and other professionals should not be compelled to participate in practices they consider morally wrong. Reproductive-rights advocates worry that broad conscience protections can reduce practical access to lawful healthcare. This is another area where the same proposal can be framed either as protecting an individual professional or restricting a patient's access.

5. Build public and parliamentary opposition through mobilisation

Right To Life UK openly describes constituency mobilisation as part of its strategy. Its online tools make contacting MPs easier. Campaigns are timed around votes and legislative threats. This is a classic political organising method: convert a national supporter base into local pressure that MPs experience as constituent opinion.

What role do litigation and “lawfare” play?

Litigation is one of the most important differences between a modern professional advocacy network and a traditional protest movement.

A protest tries to persuade the public or pressure politicians. Strategic litigation tries to change what the law means. A successful case can alter rules far beyond the individuals named in the lawsuit. Even an unsuccessful case can create publicity, attract donors, develop legal arguments and establish a pipeline of future cases.

ADF is particularly experienced in this model. Its international operation has intervened in courts and human-rights institutions across Europe. OpenDemocracy and EPF have documented the importance of strategic legal advocacy within US Christian-right activity in Europe.

The US experience shows why this matters. The overturning of Roe was not produced by one election or one protest. It required decades of litigation, scholarship, political campaigning, judicial selection and institutional development. Once a movement has a legal infrastructure, political goals that once seemed impossible can become justiciable questions waiting for the right court.

Who shares the same political circles?

Networks matter, but they must be described carefully. Sharing a conference, parliamentary group or ideological objective does not make organisations identical, and association is not proof that one actor controls another.

Still, several overlapping circles are visible.

Fiona Bruce, a former Conservative MP and Prime Ministerial Special Envoy for Freedom of Religion or Belief, appeared in ADF-linked activity and had travel expenses paid by ADF International UK for a 2023 conference, according to reporting based on the charity's accounts.

Carla Lockhart MP chairs the All-Party Parliamentary Pro-Life Group, for which Right To Life UK is secretariat.

Right To Life UK maintains relationships across party lines and explicitly says it briefs MPs and peers.

40 Days for Life, an American-origin anti-abortion campaign, has supplied a model for clinic-focused activism used in Britain.

Alliance Defending Freedom connects the British scene to a much larger US and international legal network. In America, former ADF lawyer Mike Johnson became Speaker of the House of Representatives, illustrating the organisation's proximity to senior US conservative politics even though he is not part of ADF UK's governance.

The important pattern is not a secret command structure. It is an ecosystem in which legal organisations, parliamentary advocates, grassroots campaigners, donors, religious networks and sympathetic politicians reinforce one another.

Is this “foreign interference”?

That phrase is too strong for the evidence discussed here if it implies covert or unlawful state interference.

ADF International UK is a legally registered British charity and company. Its public advocacy, litigation and contact with politicians take place through lawful channels. The UK Government has pointed to disclosure rules governing ministerial meetings, parliamentarians and APPGs.

The better issue is foreign-funded or transnational political influence. Democracies routinely permit international civil society organisations to campaign on human rights, climate, trade, religion and many other issues. Reproductive rights should not be treated differently merely because the advocacy comes from the political right.

But transparency should be strong enough for citizens to understand the scale, funding and access of actors trying to shape law. That principle should apply whether the organisation is anti-abortion, pro-choice, environmentalist, corporate or anything else.

What is the connection to the NHS?

Here is the most important evidential boundary in this article.

I have not found evidence that ADF International UK, Right To Life UK or SPUC directly influenced NHS England's policy or public wording on female sterilisation. I have not found evidence that these organisations designed the Oxfordshire policy I challenged.

The political influence documented above is primarily around abortion, assisted dying, embryo issues, freedom of religion, speech and related culture-war questions. That is already significant. There is no need to invent an unsupported sterilisation conspiracy.

Why, then, am I writing about them on a site born from my NHS sterilisation battle?

Because my concern is reproductive autonomy as a system. A political movement does not need to target my exact medical procedure before it becomes relevant to the environment in which women's reproductive choices are valued, funded or restricted.

Why does the NHS wording on female sterilisation belong in this conversation?

What you'd see today in September 2026 is that NHS England's current page on female sterilisation says that the procedure “may be available free on the NHS, or you may need to pay for your treatment.” However, this is a recent change of the past year. It changed during the Ombudsman investigation of my case with the ICB Thames Valley - before this change - NHS England's site used to state that Female Sterilisation is funded on the NHS. That's not a small change that shifts access to the procedure.

So, yes, that is extraordinary word changing for a contraceptive method on a national health-service website.

The same NHS website states elsewhere that contraception services are free and confidential on the NHS. Female sterilisation appears in the NHS list of contraceptive methods. The NHS also states that sterilisation is more than 99% effective and does not affect hormones.

Older NHS-facing information presented contraception as free more categorically, while NHS-partner Sexual Health London information reviewed in 2020 stated that female sterilisation was available free on the NHS. The current national sentence therefore does something important: it normalises the possibility that a woman seeking permanent contraception may be told the NHS will not fund it and that private payment is the alternative.

I regard that as an erosion of reproductive access and an official acknowledgement of postcode-based inequality.

Does local commissioning explain the wording?

Almost certainly it explains much of the practical variation. Sterilisation sits outside the open-access contraception services that local authorities are legally required to provide, and secondary-care commissioning can depend on NHS commissioners. Different ICBs therefore can have different pathways, thresholds and funding arrangements.

But “local commissioning” describes the mechanism; it does not answer the ethical question.

Why should a competent woman's ability to obtain a permanent contraceptive procedure through the NHS differ materially by postcode? What evidence justifies requiring her to try another method first? Are equality implications examined? How are side effects, patient preferences and the cumulative burden of long-term contraception weighed? If a man can obtain a locally commissioned vasectomy through a relatively simple route while a woman faces additional thresholds, has sex equality been properly considered?

These are the kinds of questions my complaint forced into the open.

What should we watch for if reproductive rights are eroding?

I would not look only for dramatic announcements such as “Britain bans X”. Institutional erosion is often incremental - your typical slow boil of the frog situation.

• A legal service remains technically available but becomes difficult to access.
• National guidance becomes less definite about entitlement.
• Commissioning thresholds spread from one region to another.
• Medical choice is reframed as something patients must earn after trying institutionally preferred alternatives.
• Lobbying networks expand while transparency remains weak.
• Rights debates are reframed so that restrictions appear to be merely questions of cost, conscience, safety or administrative discretion.
• People become accustomed to paying privately for something they once expected the NHS to provide.

None of these signs alone proves ideological capture. Together, however, they tell us where democratic and institutional scrutiny should be concentrated.

What can Britain learn from the United States without becoming hysterical about it?

First, rights are not self-enforcing. A right can exist in statute or precedent while access deteriorates in practice.

Second, organised minorities can have disproportionate influence when they build durable institutions. A motivated network with lawyers, policy staff, donors and relationships can shape a debate more effectively than a much larger but less organised public majority.

Third, language matters. “Religious freedom”, “women's safety”, “conscience”, “taxpayer protection”, “local choice” and “clinical discretion” can all describe legitimate concerns. They can also become vehicles through which access is narrowed. We should evaluate the practical effect of a policy, not only the label attached to it.

Fourth, transparency matters before a crisis, not after it. Once the public finally notices that an institutional norm has shifted, rebuilding the old consensus can be much harder than defending it earlier.

What do I think this movement ultimately wants?

There is no single answer because the actors differ.

Right To Life UK tells us directly that it wants human life protected from conception to natural death and works politically against liberalisation of abortion and assisted dying. ADF says it wants protection for life alongside stronger religious-freedom, conscience and free-speech rights. SPUC campaigns for legal protection of unborn children and against abortion. 40 Days for Life aims to end abortion through prayer, fasting, outreach and clinic-focused vigils.

If we take those organisations at their own words, the shared direction around abortion is clear: fewer abortions, stronger legal protection for fetal life, and resistance to reforms that make abortion easier to access or less criminalised.

Critics go further and argue that the international movement forms part of a wider campaign against sexual and reproductive rights, LGBT equality and aspects of gender equality. EPF's reports are the most detailed attempt to map that wider European ecosystem.

My own concern is narrower than claiming all of these actors are one conspiracy. I am concerned that once institutions become comfortable restricting one domain of reproductive autonomy, we should scrutinise restrictions in adjacent domains more carefully — particularly when women are told that the reproductive choice they want is not locally funded.

Why am I still pushing the NHS for accountability?

Because accountability is preventive.

My sterilisation case could be treated as an administrative dispute from 2022: one woman, one old Oxfordshire policy, one complaint. I refuse to see it that narrowly.

The failures exposed by the case raise questions about how reproductive-health policies are evidenced, who approves them, how equality is assessed, how patients challenge them and what happens when an Ombudsman finds maladministration. Those governance questions become more important — not less — in a political environment where organised groups are investing heavily in changing the boundaries of reproductive law.

I cannot tell you that ADF changed my NHS policy. The evidence does not say that.

I can tell you that a powerful US organisation deeply involved in America's reproductive-rights battles now spends more than £1 million a year through its UK arm; that it has briefed MPs and engaged senior political figures; that a domestic anti-abortion charity with more than £1 million annual income acts as secretariat to a parliamentary pro-life group; that transnational anti-rights funding in Europe is measured in hundreds of millions; and that the NHS now publicly warns women that female sterilisation may not be free where they live.

Those facts do not need embellishment. They need scrutiny.

The question Britain should ask before it is too late

The most dangerous assumption in any democracy is that “it couldn't happen here”. History rarely repeats in identical form. Britain does not need to recreate the American abortion system in order to absorb American political methods. It does not need a Supreme Court reversal to experience a gradual narrowing of reproductive access. It does not need one master organisation coordinating everything for multiple groups to push political norms in the same general direction.

Social contagion works because people adapt ideas to their own environment.

That is why I am interested in the organisations, the money, the relationships and the language now — while there is still time to ask ordinary democratic questions about them.

For the wider argument about transatlantic social contagion, the US-UK “special relationship”, America's post-Roe landscape and why the NHS female-sterilisation postcode lottery belongs in a reproductive-rights conversation, read: Is Britain Importing America's Reproductive-Rights Culture War?

References and further reading

1. Charity Commission for England and Wales. ADF International (UK), charity no. 1173195. Accounts and annual returns for year ending 30 June 2025.
2. Companies House. ADF International (UK), company no. 09923116. Filing history and company information.
3. ProPublica Nonprofit Explorer. Alliance Defending Freedom. Form 990, fiscal year ending June 2024.
4. The Guardian, Shanti Das. ‘Extreme’ US anti-abortion group ramps up lobbying in Westminster. 6 April 2024.
5. The Guardian. US anti-abortion group expands campaign in UK. 2 April 2025.
6. UK Parliament. Written Question HL6542: overseas-funded lobbying and Alliance Defending Freedom; answered 28 April 2025.
7. UK Parliament. Register of All-Party Parliamentary Groups: Pro-Life. 23 February 2026.
8. Right To Life UK. About us. Organisational description of its political, public-affairs and constituency work.
9. Charity Commission for England and Wales. The Right To Life Charitable Trust, charity no. 1099319. Accounts for year ending 31 March 2025.
10. Right To Life UK. All-Party Parliamentary Pro-Life Group.
11. European Parliamentary Forum for Sexual & Reproductive Rights. Tip of the Iceberg. 2021.
12. European Parliamentary Forum for Sexual & Reproductive Rights. The Next Wave: How Religious Extremism Is Reclaiming Power. 2025.
13. openDemocracy. UK government cites US anti-LGBT ‘hate group’ in free speech proposals. 2021.
14. openDemocracy. Christian ‘legal army’ in hundreds of court battles worldwide. 2017.
15. openDemocracy. Revealed: Files expose ‘culture war’ ties between anti-abortion groups and Brexit. 2021.
16. Supreme Court of the United States / Cornell Legal Information Institute. Dobbs v Jackson Women's Health Organization, 2022.
17. Guttmacher Institute. State Bans on Abortion Throughout Pregnancy. Updated September 2026.
18. The White House. Enforcing the Hyde Amendment. 24 January 2025.
19. The White House. Memorandum on the Mexico City Policy. 24 January 2025.
20. NHS. Finding out about female sterilisation. Reviewed 14 February 2024.
21. NHS. Where to get contraception.
22. Department of Health and Social Care. The NHS Constitution for England and handbook.
23. Sexual Health London. Female sterilisation. Clinical content reviewed December 2020.

Editorial note: The presence of shared political circles, funding streams or similar policy objectives should not be interpreted as proof that organisations are centrally coordinated. This article distinguishes documented relationships from inference and does not claim a direct causal link between anti-abortion advocacy organisations and NHS female-sterilisation commissioning.